MARKET

SRDX

SRDX

Surmodics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

58.35
+0.18
+0.31%
Closed 16:31 09/17 EDT
OPEN
58.54
PREV CLOSE
58.17
HIGH
59.62
LOW
55.59
VOLUME
185.12K
TURNOVER
--
52 WEEK HIGH
62.27
52 WEEK LOW
35.17
MARKET CAP
809.43M
P/E (TTM)
570.94
1D
5D
1M
3M
1Y
5Y
Is Now An Opportune Moment To Examine Surmodics, Inc. (NASDAQ:SRDX)?
Surmodics, Inc. ( NASDAQ:SRDX ), might not be a large cap stock, but it saw a decent share price growth in the teens...
Simply Wall St. · 6d ago
Needham & Co Adjusts SurModics PT to $76 From $68, Maintains Buy Rating
MT Newswires · 09/08 13:02
--Needham Adjusts SurModics' Price Target to $76 from $68, Keeps Buy Rating
MT Newswires · 09/08 12:33
Needham Maintains Buy on Surmodics, Raises Price Target to $76
Needham analyst Mike Matson maintains Surmodics (NASDAQ:SRDX) with a Buy and raises the price target from $68 to $76.
Benzinga · 09/08 10:10
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)
Benzinga · 09/02 12:19
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 11:32
HRC vs. SRDX: Which Stock Is the Better Value Option?
Zacks.com · 08/26 08:41
Soleus Capital Management, L.P. Buys BioAtla Inc, NeuroPace Inc, C4 Therapeutics Inc, Sells ...
GuruFocus News · 08/23 21:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRDX. Analyze the recent business situations of Surmodics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SRDX stock price target is 76.25 with a high estimate of 83.00 and a low estimate of 70.00.
EPS
Institutional Holdings
Institutions: 206
Institutional Holdings: 12.85M
% Owned: 92.62%
Shares Outstanding: 13.87M
TypeInstitutionsShares
Increased
49
546.29K
New
16
61.40K
Decreased
53
352.39K
Sold Out
7
103.81K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.65%
Key Executives
Non-Executive Chairman/Independent Director
Susan Knight
Chief Executive Officer/President/Director
Gary Maharaj
Chief Financial Officer/Senior Vice President - Finance
Timothy Arens
Senior Vice President/Chief Marketing Officer
Teri Sides
Senior Vice President/General Counsel/Secretary
Gordon Weber
Senior Vice President/General Manager
Joseph Stich
Senior Vice President
Charles Olson
Vice President
Nusrath Sultana
Independent Director
Jose Bedoya
Independent Director
David Dantzker
Independent Director
Lisa Heine
Independent Director
Ronald Kalich
No Data
About SRDX
Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company's Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company's In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.

Webull offers kinds of SurModics, Inc. stock information, including NASDAQ:SRDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRDX stock methods without spending real money on the virtual paper trading platform.